Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (537) 537
humans (343) 343
animals (291) 291
polyglutamic acid - analogs & derivatives (268) 268
polyglutamic acid - chemistry (239) 239
pharmacology & pharmacy (183) 183
female (180) 180
mice (164) 164
nanoparticles (137) 137
male (136) 136
polyglutamic acid - metabolism (106) 106
polyglutamic acid - therapeutic use (96) 96
poly (95) 95
methotrexate - analogs & derivatives (91) 91
cancer (88) 88
drug delivery systems (87) 87
cell line, tumor (83) 83
materials science, biomaterials (80) 80
glutamate (71) 71
polyglutamic acid - administration & dosage (70) 70
oncology (68) 68
drug carriers - chemistry (67) 67
rats (66) 66
methotrexate (64) 64
nanoparticles - chemistry (64) 64
particle size (64) 64
polymers (64) 64
chemistry, multidisciplinary (61) 61
methotrexate - therapeutic use (61) 61
drug-delivery (60) 60
engineering, biomedical (59) 59
methotrexate - metabolism (55) 55
drugs (52) 52
in-vivo (52) 52
paclitaxel - analogs & derivatives (52) 52
polyglutamic acid - pharmacology (52) 52
cell survival - drug effects (51) 51
middle aged (49) 49
polyethylene glycols - chemistry (49) 49
cells (48) 48
polyglutamic acid (48) 48
polymers - chemistry (48) 48
paclitaxel (47) 47
analysis (45) 45
chemotherapy (45) 45
mice, inbred balb c (45) 45
therapy (45) 45
antineoplastic agents - administration & dosage (44) 44
in-vitro (43) 43
aged (42) 42
antineoplastic agents - therapeutic use (41) 41
biochemistry & molecular biology (41) 41
cell line (41) 41
polyglutamic acid - blood (41) 41
delivery (40) 40
micelles (40) 40
drug delivery (39) 39
adult (38) 38
tumors (38) 38
vehicles (38) 38
amino acids (37) 37
mice, inbred c57bl (36) 36
mice, nude (36) 36
neoplasms - drug therapy (36) 36
toxicity (36) 36
doxorubicin (35) 35
chitosan (34) 34
hydrogen-ion concentration (33) 33
nanoscience & nanotechnology (33) 33
paclitaxel - administration & dosage (33) 33
proteins (33) 33
gene delivery (32) 32
kinetics (32) 32
methotrexate - blood (32) 32
pharmacokinetics (32) 32
polyglutamic acid - pharmacokinetics (32) 32
dose-response relationship, drug (31) 31
glutamic acid (31) 31
article (30) 30
paclitaxel - therapeutic use (30) 30
polyglutamic acid - chemical synthesis (30) 30
tumor (30) 30
arthritis, rheumatoid - drug therapy (29) 29
antineoplastic agents - pharmacology (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
chitosan - chemistry (28) 28
glutaminsäure (28) 28
methotrexate - pharmacokinetics (28) 28
tissue distribution (28) 28
treatment outcome (28) 28
lung neoplasms - drug therapy (27) 27
research (27) 27
acids (26) 26
antirheumatic agents - therapeutic use (26) 26
child (26) 26
cytotoxicity (26) 26
drug carriers (26) 26
drug delivery systems - methods (26) 26
efficacy (26) 26
erythrocytes - metabolism (26) 26
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel
by Eldar-Boock, Anat and Miller, Keren and Sanchis, Joaquin and Lupu, Ruth and Vicent, María J and Satchi-Fainaro, Ronit
Biomaterials, ISSN 0142-9612, 2011, Volume 32, Issue 15, pp. 3862 - 3874
Abstract Angiogenesis plays a prominent role in cancer progression. Anti-angiogenic therapy therefore, either alone or in combination with conventional... 
Advanced Basic Science | Dentistry | Angiogenesis | Integrin | Polyglutamic acid | Polymer therapeutics | Paclitaxel | RGD peptidomimetic | MATERIALS SCIENCE, BIOMATERIALS | RGD PEPTIDES | ENGINEERING, BIOMEDICAL | PS 2 PATIENTS | BRAIN-TUMORS | CELL LUNG-CANCER | BREAST-CANCER | CONJUGATE | POLIGLUMEX CT-2103 | INHIBITORS | CATHEPSIN-B | Paclitaxel - metabolism | Rats, Wistar | Humans | Polyglutamic Acid - administration & dosage | Integrins - metabolism | Drug Delivery Systems | Polyglutamic Acid - analogs & derivatives | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Antineoplastic Agents, Phytogenic - metabolism | Antineoplastic Agents, Phytogenic - therapeutic use | Paclitaxel - administration & dosage | Oligopeptides - chemistry | Polyglutamic Acid - metabolism | Paclitaxel - analogs & derivatives | Rats | Antineoplastic Agents, Phytogenic - chemistry | Cathepsin B - metabolism | Oligopeptides - metabolism | Paclitaxel - therapeutic use | Neoplasms - drug therapy | Polyglutamic Acid - chemistry | Animals | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Polyglutamic Acid - therapeutic use | Drugs | Drug delivery systems | Biological products | Endothelial growth factors | Development and progression | Permeability | Antineoplastic agents | Cells | Endothelium | Vehicles | Antimitotic agents | Fibrin | Fibrinogen | Physiological aspects | Polymer industry | Polymers | Vascular endothelial growth factor | Tumors | Integrins | Index Medicus | paclitaxel | polymer therapeutics | integrin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Poly-Gamma-Glutamic Acid (-PGA)-based encapsulation of adenovirus to evade neutralizing antibodies
by Khalil, Ibrahim R and Khechara, Martin P and Kurusamy, Sathishkumar and Armesilla, Angel L and Gupta, Abhishek and Mendrek, Barbara and Khalaf, Tamara and Scandola, Mariastella and Focarete, Maria Letizia and Kowalczuk, Marek and Radecka, Iza
Molecules, ISSN 1420-3049, 10/2018, Volume 23, Issue 10, p. 2565
In recent years, there has been an increasing interest in oncolytic adenoviral vectors as an alternative anticancer therapy. The induction of an immune... 
Chitosan | PGA | Immunogenicity | Adenovirus | Biodegradable polymer | chitosan | biodegradable polymer | BIOCHEMISTRY & MOLECULAR BIOLOGY | BACILLUS-LICHENIFORMIS | gamma-PGA | CHILDHOOD | CHEMISTRY, MULTIDISCIPLINARY | immunogenicity | BIOPOLYMER FLOCCULANT | NANOPARTICLES | CANCER-TREATMENT | IMMUNE-RESPONSES | adenovirus | LYMPHOMA | GENE-THERAPY | ANTHRACIS | ONCOLYTIC ADENOVIRUS | Drug Carriers - therapeutic use | Nanoparticles - chemistry | Humans | Drug Carriers - chemistry | Polyglutamic Acid - analogs & derivatives | Polymers - therapeutic use | Antibodies, Neutralizing - immunology | Neoplasms - therapy | Immunity, Cellular - drug effects | Nanoparticles - therapeutic use | Chitosan - therapeutic use | Adenoviridae - genetics | Adenoviridae - immunology | Oncolytic Virotherapy - adverse effects | Chitosan - immunology | Oncolytic Viruses - genetics | Polyglutamic Acid - immunology | Antibodies, Neutralizing - drug effects | Polyglutamic Acid - chemistry | Chitosan - chemistry | Neoplasms - immunology | Oncolytic Viruses - immunology | Ligands | Polymers - chemistry | Polyglutamic Acid - therapeutic use | Index Medicus | γ-PGA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The in vivo behavior and antitumor activity of doxorubicin-loaded poly(γ-benzyl l -glutamate)- block -hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice
by Upadhyay, Kamal Kumar, PhD and Mishra, Anil Kumar, PhD and Chuttani, Krishna, MSc and Kaul, Ankur, MSc and Schatz, Christophe, PhD and Le Meins, Jean-François, PhD and Misra, Ambikanandan, PhD and Lecommandoux, Sebastien, PhD
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2012, Volume 8, Issue 1, pp. 71 - 80
Abstract The in vivo efficacy of doxorubicin (DOX)-loaded poly(γ-benzyl l -glutamate)- block -hyaluronan (PBLG23 - b -HYA10 )-based polymersomes (PolyDOX) was... 
Internal Medicine | Hyaluronan | Ehrlich ascites tumor (EAT) | Antitumor activity | Doxorubicin | Polymersomes | MEDICINE, RESEARCH & EXPERIMENTAL | BLOCK-COPOLYMERS | SOLID TUMORS | DRUG-DELIVERY | RECEPTOR | NANOSCIENCE & NANOTECHNOLOGY | VASCULAR-PERMEABILITY | CANCER | CARRIERS | PACLITAXEL | LIPOSOMAL DOXORUBICIN | ENDOCYTOSIS HARE | Doxorubicin - blood | Doxorubicin - therapeutic use | Drug Carriers - adverse effects | Hyaluronic Acid - therapeutic use | Nanoparticles - chemistry | Antineoplastic Agents - chemical synthesis | Humans | Drug Carriers - administration & dosage | Polyglutamic Acid - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Nanoparticles - adverse effects | Drug Carriers - chemistry | Polyglutamic Acid - analogs & derivatives | Antineoplastic Agents - adverse effects | Female | Hyaluronic Acid - blood | Hyaluronic Acid - adverse effects | Doxorubicin - administration & dosage | Endocytosis - immunology | Technetium - chemistry | Rabbits | Hyaluronic Acid - administration & dosage | Hyaluronic Acid - chemistry | Carcinoma, Ehrlich Tumor - drug therapy | Doxorubicin - chemical synthesis | Polyglutamic Acid - blood | Polyglutamic Acid - chemistry | Animals | Hyaluronic Acid - analogs & derivatives | Antineoplastic Agents - blood | Hyaluronan Receptors - immunology | Mice | Mice, Inbred BALB C | Nanoparticles - administration & dosage | Polyglutamic Acid - therapeutic use | Neoplasms, Experimental - drug therapy | Doxorubicin - adverse effects | Polyglutamic Acid - adverse effects | Anthracyclines | Ascites | Hyaluronic acid | Tumors | Index Medicus | Polymers | Chemical Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
by Paz-Ares, L and Ross, H and O'Brien, M and Riviere, A and Gatzemeier, U and Von Pawel, J and Kaukel, E and Freitag, L and Digel, W and Bischoff, H and García-Campelo, R and Iannotti, N and Reiterer, P and Bover, I and Prendiville, J and Eisenfeld, A.J and Oldham, F.B and Bandstra, B and Singer, J.W and Bonomi, P
British Journal of Cancer, ISSN 0007-0920, 05/2008, Volume 98, Issue 10, pp. 1608 - 1613
Paclitaxel poliglumex (PPX), a macromolecule drug conjugate linking paclitaxel to polyglutamic acid, reduces systemic exposure to peak concentrations of free... 
Poliglumex | Lung cancer | Docetaxel | lung cancer | MACROMOLECULAR THERAPEUTICS | ONCOLOGY | docetaxel | XYOTAX | TUMOR | poliglumex | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Polyglutamic Acid - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Patient Selection | Polyglutamic Acid - analogs & derivatives | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Paclitaxel - administration & dosage | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Drug Administration Schedule | Paclitaxel - analogs & derivatives | Paclitaxel - adverse effects | Treatment Outcome | Paclitaxel - therapeutic use | Taxoids - administration & dosage | Quality of Life | Aged | Polyglutamic Acid - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Polyglutamic Acid - adverse effects | Index Medicus | Clinical Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Tumor‐targeted chemotherapy with the nanopolymer‐based drug NC‐6004 for oral squamous cell carcinoma
by Endo, Kazuhira and Ueno, Takayoshi and Kondo, Satoru and Wakisaka, Naohiro and Murono, Shigeyuki and Ito, Makoto and Kataoka, Kazunori and Kato, Yasuki and Yoshizaki, Tomokazu
Cancer Science, ISSN 1347-9032, 03/2013, Volume 104, Issue 3, pp. 369 - 374
Cisplatin ( CDDP ) has been a key drug for chemotherapy in patients with head and neck squamous cell carcinoma. Nephrotoxicity is one of its adverse reactions... 
HEAD | LYMPH-NODE METASTASIS | SOLID TUMORS | CISPLATIN | ONCOLOGY | INCORPORATED POLYMERIC MICELLES | ANTICANCER DRUG | BLOCK-COPOLYMER | CANCER | DELIVERY | NEPHROTOXICITY | Neoplasm Transplantation | Kidney - drug effects | Mouth Neoplasms - drug therapy | Carcinoma, Squamous Cell - pathology | Humans | Male | Polyglutamic Acid - administration & dosage | Lymphatic Metastasis | Tongue Neoplasms - pathology | Tongue Neoplasms - drug therapy | Polyglutamic Acid - analogs & derivatives | Organoplatinum Compounds - administration & dosage | Animals | Carcinoma, Squamous Cell - drug therapy | Cisplatin - therapeutic use | Mice, Nude | Nanoparticles - therapeutic use | Micelles | Cell Line, Tumor | Mice | Polyglutamic Acid - therapeutic use | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Polyglutamic Acid - adverse effects | Chemotherapy | Squamous cell carcinoma | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Characterization of poly(L‐glutamic acid)‐grafted hyaluronan as a novel candidate medicine and biomedical device for intra‐articular injection
by Muramatsu, Kazuaki and Tajima, Yuya and Kaneko, Rin and Yanagita, Yuta and Hirai, Hiroyuki and Hiura, Nana
Journal of Biomedical Materials Research Part A, ISSN 1549-3296, 11/2017, Volume 105, Issue 11, pp. 3006 - 3016
A novel hyaluronan (HA) derivative, poly(L‐glutamic acid)‐grafted hyaluronan (PGA‐g‐HA), was synthesized to improve the durability of conventional HA products... 
poly(L‐glutamic acid) | intra‐articular injection | hyaluronan | cartilage | intra-articular injection | poly(L-glutamic acid) | RHEUMATOID-ARTHRITIS | MATERIALS SCIENCE, BIOMATERIALS | MOLECULAR-WEIGHT | CARTILAGE DEGENERATION | SYNOVIAL-FLUID | ENGINEERING, BIOMEDICAL | CROSS-LINKED HYALURONATE | SODIUM HYALURONATE | TERTIARY STRUCTURES | AQUEOUS-SOLUTION | HYLAN G-F-20 | KNEE OSTEOARTHRITIS | Viscosity | Hyaluronic Acid - therapeutic use | Hyaluronic Acid - administration & dosage | Chondrocytes - immunology | Cells, Cultured | Hyaluronic Acid - chemistry | Elasticity | Male | Polyglutamic Acid - administration & dosage | Rats, Sprague-Dawley | Chondrocytes - drug effects | Polyglutamic Acid - chemistry | Animals | Anti-Inflammatory Agents - chemistry | Injections, Intra-Articular | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Osteoarthritis, Knee - immunology | Polyglutamic Acid - therapeutic use | Osteoarthritis, Knee - drug therapy | Glutamate | Hyaluronic acid | Amino acids | Viscoelasticity | Knee | Glutamic acid | Antiinflammatory agents | Storage modulus | Dendritic cells | Syngeneic grafts | Durability | Knee (anatomy) | Inflammation | Loss modulus | Injection | Grafting | Biological activity | Medicine | Hyaluronan | Biomedical materials | Acids | Immunogenicity | Chondrocytes | Interleukin 1 | Bone marrow | Biocompatibility | Osteoarthritis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
by Langer, Corey J and O’Byrne, Kenneth J and Socinski, Mark A and Mikhailov, Sergei M and Leśniewski-Kmak, Krzysztof and Smakal, Martin and Ciuleanu, Tudor E and Orlov, Sergey V and Dediu, Mircea and Heigener, David and Eisenfeld, Amy J and Sandalic, Larissa and Oldham, Fred B and Singer, Jack W and Ross, Helen J
Journal of Thoracic Oncology, ISSN 1556-0864, 06/2008, Volume 3, Issue 6, pp. 623 - 630
Performance status (PS) 2 patients with non-small cell lung cancer (NSCLC) experience more toxicity, lower response rates, and shorter survival times than... 
PS 2 | PPX | CT-2103 | Paclitaxel poliglumex | Toxicity | Non-small cell lung cancer | non-small cell lung cancer | toxicity | SURVIVAL | paclitaxel poliglumex | SOLID TUMORS | REGIMENS | RANDOMIZED TRIAL | SINGLE-AGENT | ONCOLOGY | RESPIRATORY SYSTEM | Lung Neoplasms - drug therapy | United States - epidemiology | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Polyglutamic Acid - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Polyglutamic Acid - analogs & derivatives | Carboplatin - therapeutic use | Aged, 80 and over | Adult | Female | Retrospective Studies | Paclitaxel - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Survival Rate - trends | Paclitaxel - analogs & derivatives | Carboplatin - administration & dosage | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Paclitaxel - therapeutic use | Disease-Free Survival | Quality of Life | Aged | Polyglutamic Acid - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Targeting NCAM-expressing neuroblastoma with polymeric precision nanomedicine
by Markovsky, Ela and Eldar-Boock, Anat and Ben-Shushan, Dikla and Baabur-Cohen, Hemda and Yeini, Eilam and Pisarevsky, Evgeni and Many, Ariel and Aviel-Ronen, Sarit and Barshack, Iris and Satchi-Fainaro, Ronit
Journal of Controlled Release, ISSN 0168-3659, 03/2017, Volume 249, pp. 162 - 172
Neural cell adhesion molecule (NCAM) expression is known to be associated with an aggressive biological behavior, increased metastatic capacity and expression... 
Neural cell adhesion molecule | Neuroblastoma | Polyglutamic acid | Polymer-drug conjugates | Polymeric nanomedicines | Paclitaxel | CELL-ADHESION MOLECULE | ISOFORMS | PACLITAXEL POLIGLUMEX | CHEMISTRY, MULTIDISCIPLINARY | BRAIN-TUMORS | BREAST-CANCER | LUNG-CANCER | ENDOTHELIAL-CELLS | MIMETIC PEPTIDES | PHARMACOLOGY & PHARMACY | CD56 | CATHEPSIN-B | Human Umbilical Vein Endothelial Cells | Paclitaxel - metabolism | Humans | Polyglutamic Acid - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Drug Delivery Systems | Antineoplastic Agents - metabolism | Polyglutamic Acid - analogs & derivatives | Paclitaxel - chemistry | Peptides - metabolism | Paclitaxel - administration & dosage | Nanomedicine | Neuroblastoma - pathology | Drug Carriers - metabolism | Polyglutamic Acid - metabolism | Peptides - chemistry | Paclitaxel - analogs & derivatives | Antineoplastic Agents - chemistry | Mice, SCID | Paclitaxel - therapeutic use | Polyglutamic Acid - chemistry | Animals | Neuroblastoma - drug therapy | Neural Cell Adhesion Molecules - metabolism | Cell Line, Tumor | Neuroblastoma - metabolism | Polyglutamic Acid - therapeutic use | Polymers | Stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease
by Conejos-Sánchez, Inmaculada and Cardoso, Isabel and Oteo-Vives, Marta and Romero-Sanz, Eduardo and Paul, Alison and Sauri, Amparo Ruiz and Morcillo, Miguel A and Saraiva, Maria J and Vicent, María J
Journal of Controlled Release, ISSN 0168-3659, 01/2015, Volume 198, pp. 80 - 90
The term amyloidosis describes neurological diseases where an abnormal protein is misfolded and accumulated as deposits in organs and tissues, known as... 
Rare diseases | Drug delivery | Polymer-drug conjugate | Polymeric drug | Amyloid disrupters | Polymer therapeutics | THERAPEUTICS | POLYNEUROPATHY | ACID | DRUG-DELIVERY | TRANSTHYRETIN AMYLOIDOSIS | PACLITAXEL POLIGLUMEX | MODEL | CANCER | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | PHARMACOLOGY & PHARMACY | TRANSGENIC MICE | Hemolysis | Doxycycline - chemistry | Doxycycline - therapeutic use | Doxycycline - pharmacokinetics | Rats | Mice, Transgenic | Erythrocytes - drug effects | Tissue Distribution | Polyglutamic Acid - chemistry | Polyglutamic Acid - pharmacokinetics | Animals | Polyglutamic Acid - pharmacology | Plasma - chemistry | Amyloid - drug effects | Amyloid Neuropathies, Familial - drug therapy | Drug Liberation | Doxycycline - pharmacology | Mice, Inbred BALB C | Polyglutamic Acid - therapeutic use | Disease Models, Animal | Care and treatment | Doxycycline | Development and progression | Amyloidosis | Polymer industry | Polymers | Alzheimer's disease | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
by O'Brien, Mary E.R and Socinski, Mark A and Popovich, Alexander Y and Bondarenko, Igor N and Tomova, Antoaneta and Bilynsky˘ı, Borys T and Hotko, Yevhen S and Ganul, Valentin L and Kostinsky, Ippolit Y and Eisenfeld, Amy J and Sandalic, Larissa and Oldham, Fred B and Bandstra, Bruce and Sandler, Alan B and Singer, Jack W
Journal of Thoracic Oncology, ISSN 1556-0864, 07/2008, Volume 3, Issue 7, pp. 728 - 734
Patients with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS ≥ 2) have limited life expectancies and decreased tolerance for... 
PS 2 | PPX | CT-2103 | Paclitaxel poliglumex | Toxicity | Non-small cell lung cancer | non-small cell lung cancer | toxicity | PERFORMANCE STATUS | paclitaxel poliglumex | ONCOLOGY | RESPIRATORY SYSTEM | XYOTAX(TM) | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Paclitaxel - analogs & derivatives | Male | Survival Rate | Carcinoma, Non-Small-Cell Lung - mortality | Paclitaxel - therapeutic use | Polyglutamic Acid - analogs & derivatives | Antimetabolites, Antineoplastic - therapeutic use | Deoxycytidine - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Deoxycytidine - adverse effects | Female | Polyglutamic Acid - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - therapeutic use | Deoxycytidine - analogs & derivatives | Antineoplastic Agents, Phytogenic - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Complete regression of well-established tumors using a novel water- soluble poly(L-glutamic acid)-paclitaxel conjugate
by Li, Chun and Yu, Dong-Fang and Newman, Robert A and Cabral, Fernando and Stephens, L. Clifton and Hunter, Nancy and Milas, Luka and Wallace, Sidney
Cancer Research, ISSN 0008-5472, 06/1998, Volume 58, Issue 11, pp. 2404 - 2409
Despite an intensive search, few water-soluble paclitaxel derivatives have been shown to have a therapeutic index superior to paclitaxel itself, We non report... 
POLYMERS | DESIGN | INVIVO | ONCOLOGY | ANTICANCER AGENTS | TAXOL | PRODRUGS | ANTITUMOR-ACTIVITY | DRUG-DELIVERY SYSTEMS | DERIVATIVES | Water | Cricetinae | Apoptosis - drug effects | Paclitaxel - analogs & derivatives | Solubility | Rats | Antineoplastic Agents - therapeutic use | Paclitaxel - therapeutic use | Remission Induction | Neoplasms, Experimental - pathology | Animals | Taxoids | Microtubules - drug effects | Mice | Polyglutamic Acid - therapeutic use | Antineoplastic Agents, Phytogenic - therapeutic use | Neoplasms, Experimental - drug therapy | CHO Cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Paclitaxel-loaded poly(γ-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system against cultured HepG2 cells
by Liang, Hsiang-Fa and Chen, Sung-Ching and Chen, Mei-Chin and Lee, Po-Wei and Chen, Chiung-Tong and Sung, Hsing-Wen
Bioconjugate Chemistry, ISSN 1043-1802, 03/2006, Volume 17, Issue 2, pp. 291 - 299
The study was to develop paclitaxel-loaded formulations using a novel type of self-assembled nanoparticles that was composed of block copolymers synthesized... 
CIRCULATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | BACILLUS-LICHENIFORMIS | GLUTAMIC ACID | BIOCHEMICAL RESEARCH METHODS | CROSS-LINKING | CHEMISTRY, ORGANIC | CHEMISTRY, MULTIDISCIPLINARY | CARRIER | IN-VITRO | PLASMID DNA | CARBODIIMIDE | GENIPIN | BIOLOGICAL TISSUES | Taxoids - chemistry | Polyglutamic Acid - metabolism | Polyesters - therapeutic use | Humans | Paclitaxel - analogs & derivatives | Galactosamine - chemistry | Antineoplastic Agents, Phytogenic - chemistry | Taxoids - metabolism | Drug Delivery Systems | Polyesters - chemistry | Polyglutamic Acid - chemistry | Taxoids - therapeutic use | Polyesters - metabolism | Cell Line, Tumor | Nanostructures - chemistry | Antineoplastic Agents, Phytogenic - metabolism | Molecular Structure | Polyglutamic Acid - therapeutic use | Antineoplastic Agents, Phytogenic - therapeutic use | Nanoparticles | Medical research | Liver | Biochemistry | Drug therapy | Polymers | Cells | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies
by Jade Homsi and George R. Simon and Chris R. Garrett and Gregory Springett and Ronald De Conti and Alberto A. Chiappori and Pamela N. Munster and Michelle K. Burton and Scott Stromatt and Claudia Allievi and Patrizia Angiuli and Amy Eisenfeld and Daniel M. Sullivan and Adil I. Daud
Clinical Cancer Research, ISSN 1078-0432, 10/2007, Volume 13, Issue 19, pp. 5855 - 5861
Purpose: CT-2106 is a 20( S )-camptothecin poly- l -glutamate conjugate. This linkage stabilizes the active lactone form of camptothecin and enhances aqueous... 
pharmacokinetics | camptothecins | CT-2106 | Phase I-III Clinical Trials | EVERY 3 WEEKS | EFFICACY | PHARMACOKINETICS | ONCOLOGY | POLY(L-GLUTAMIC ACID) | STABILITY | DELIVERY-SYSTEMS | CONJUGATE | INHIBITORS | CANCER | NSC-100880 | Neoplasms - metabolism | Camptothecin - therapeutic use | Drug Administration Schedule | Humans | Middle Aged | Solubility | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasms - drug therapy | Polyglutamic Acid - analogs & derivatives | Maximum Tolerated Dose | Time Factors | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Aged | Polyglutamic Acid - therapeutic use | Camptothecin - analogs & derivatives | Lactones - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights